CClinicalTrials.gg
CompletedNCT05393583IDAHUpdated Jan 8, 2024

In-hospital Versus DAy Care Hysterectomy in Transgender Men

An interventional study of Outpatient hysterectomy and Inpatient hysterectomy in Outpatient Hysterectomy in Transmen, sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Jan 2019, registered Jan 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

In this trial 2 groups of transmen who are getting a hysterectomy will be compared: inpatient vs outpatient.

Read the detailed description

In this trial transmen who consultate for a hysterectomy are randomised over 2 groups: inpatient vs outpatient.

In the inpatient group the participant stays 1 night in the hospital after the laparoscopic hysterectomy. The outpatient group can leave the hospital the day of the operation. Standard care after laparoscopic hysterectomy is 2 nights hospital stay.

Through this trial the investigators would like to answer following questions:

  • Is hysterectomy in dayclinic as safe as a hysterectomy in an outpatient setting?
  • Is there a higher complication/re-admission rate with hysterectomy in outpatient setting?
  • Are patients as satisfied with the length of hospital stay in an inpatient hysterectomy?
  • Is the need for pain medication higher in the inpatient group? Do this patients experience more postoperative pain?
  • Is there a loss in 'quality of life' with hysterectomy in inpatient setting?
  • Are patients who have the hysterectomy in dayclinic more anxious/worried?

The primary objective is the satisfaction of the patient with the length of hospital stay. The other indicators will be seen as secondary outcomes.

02

Conditions studied

  • Outpatient Hysterectomy in Transmen
03

In context

Lead sponsor

University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • transgender man
  • 18y or older
  • registers for a total hysterectomy at the genderclinic of UZ Gent.

Exclusion criteria

Exclusion Criteria:

  • simultaneous planned breast surgery/scar corrections
  • ASA score 3-4
  • persons with mental retardation or severe psychiatric disorder
  • persons without an adult caretaker / partner present the first night after discharge from the hospital
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Outpatient

    Discharge on the day of hysterectomy

    Procedure: Outpatient hysterectomy

  • Active comparator
    Inpatient

    Discharge after 1 night stay in the hospital

    Procedure: Inpatient hysterectomy

Interventions

  • ProcedureOutpatient hysterectomy

    Discharge on the day of the hysterectomy

  • ProcedureInpatient hysterectomy

    1 night hospital stay after hysterectomy

06

What researchers measure

Primary outcomes

  1. Satisfaction with the length of hospital stay after 1 week assessed by the VAS (visual analogue scale)

    Satisfaction of the patient with the length of hospital stay 1 week after surgery assessed by a Visual Analogue Scale ranging from 0 to 100 (with 100 being extremely satisfied)

    Time frame: Day 7

  2. Satisfaction with the length of hospital stay after 6 weeks assessed by the VAS (visual analogue scale)

    Satisfaction of the patient with the length of hospital stay 6 weeks after surgery assessed by a Visual Analogue Scale ranging from 0 to 100 (with 100 being extremely satisfied)

    Time frame: Day 42

Secondary outcomes

  1. Pain scores

    Pain will be measured by using a Visual Analogue Scale for pain ranging from 0 to 10 (with 10 being the worst pain ever)

    Time frame: Day 0 to 7

  2. Analgesics use

    The amount of analgesics used every day

    Time frame: Day 0 to 7

  3. Type and number of intra-operative complications

    Time frame: Day 0

  4. Type and number of postoperative complications

    Time frame: Day 42

  5. Readmission rate

    Time frame: Day 42

  6. Postoperative quality of recovery (QoR)-15 score

    The QoR-15 is a patient-reported outcome questionnaire that measures the quality of recovery after surgery and anaesthesia. Each question is scored from 0 (= "none of the time") to 10 (= "all of the time") for positive items; for negative items the scoring is reversed (maximum score 150).

    Time frame: Day 1, day 2 and day 42

  7. Postoperative wellbeing through the Hospital Anxiety and Depression Scale (HADS)

    Postoperative wellbeing will be assessed by using the HADS. The HADS is a 14-question instrument that measures anxiety and depression. Each question is scored between 0 (no impairment) and 3 (severe impairment), with a maximum score of 21 for anxiety or depression.

    Time frame: Day 1, day 2 and day 42

07

Study locations

1 site
  • University Hospital Ghent
    Ghent, Belgium
08

References and documents

Publications

  • Dedden SJ, Geomini PMAJ, Huirne JAF, Bongers MY. Vaginal and Laparoscopic hysterectomy as an outpatient procedure: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:212-223. doi: 10.1016/j.ejogrb.2017.07.015. Epub 2017 Jul 22. PubMed 28810192 ↗
  • Kisic-Trope J, Qvigstad E, Ballard K. A randomized trial of day-case vs inpatient laparoscopic supracervical hysterectomy. Am J Obstet Gynecol. 2011 Apr;204(4):307.e1-8. doi: 10.1016/j.ajog.2010.11.014. Epub 2011 Jan 26. PubMed 21272844 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05393583
Lead sponsor
University Hospital, Ghent
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jan 25, 2019
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Last update
Jan 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion